NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital
NRx Pharmaceuticals (NASDAQ:NRXP) presented at the Global Passion Project symposium, announcing plans for the Fall 2025 launch of HOPE Therapeutics clinics. The company introduced a groundbreaking residential program combining neuroplastic treatments including ketamine, transcranial magnetic stimulation, and hyperbaric oxygen therapy for treating suicidal depression, PTSD, and cognitive dysfunction.
The company recently secured $8.8 million in funding from biotech investors through a clean common stock offering. Notable developments include Matthew Rockefeller joining HOPE Therapeutics' Advisory Board and plans for establishing a flagship location in Palm Beach, FL. The combined treatment approach aims to achieve over 90% response rates, significantly higher than the 60% rates typically seen with individual therapies.
NRx Pharmaceuticals (NASDAQ:NRXP) ha presentato al simposio Global Passion Project i piani per il lancio nell'autunno 2025 delle cliniche HOPE Therapeutics. L'azienda ha illustrato un programma residenziale innovativo che combina trattamenti neuroplastici come ketamina, stimolazione magnetica transcranica e ossigenoterapia iperbarica per il trattamento della depressione suicidaria, del disturbo da stress post-traumatico e del deterioramento cognitivo.
Di recente la società ha ottenuto 8,8 milioni di dollari di finanziamento da investitori biotech tramite un'offerta di azioni ordinarie. Tra gli sviluppi rilevanti figurano l'ingresso di Matthew Rockefeller nel comitato consultivo di HOPE Therapeutics e i piani per una sede principale a Palm Beach, FL. L'approccio terapeutico combinato punta a raggiungere oltre il 90% di tassi di risposta, molto superiori al 60% tipico delle singole terapie.
NRx Pharmaceuticals (NASDAQ:NRXP) se presentó en el simposio Global Passion Project y anunció planes para lanzar en el otoño de 2025 las clínicas HOPE Therapeutics. La compañía presentó un innovador programa residencial que combina tratamientos de neuroplasticidad, incluida la ketamina, la estimulación magnética transcraneal y la terapia de oxígeno hiperbárico, para tratar la depresión suicida, el TEPT y el deterioro cognitivo.
Recientemente la empresa aseguró 8,8 millones de dólares en financiación de inversores biotecnológicos mediante una oferta de acciones ordinarias. Entre los avances destacables están la incorporación de Matthew Rockefeller al Consejo Asesor de HOPE Therapeutics y los planes de establecer una sede emblemática en Palm Beach, FL. El enfoque combinado de tratamiento aspira a alcanzar más del 90% de tasas de respuesta, muy por encima del 60% habitual con terapias individuales.
NRx Pharmaceuticals (NASDAQ:NRXP)는 Global Passion Project 심포지엄에서 2025년 가을 HOPE Therapeutics 클리닉 개설 계획을 발표했습니다. 회사는 자살 위험 우울증, PTSD(외상후스트레스장애), 인지 기능 저하 치료를 위해 케타민, 경두개 자기자극술(TMS), 고압산소치료 등 신경가소성 치료를 결합한 혁신적인 입원 프로그램을 소개했습니다.
회사 측은 최근 보통주 공모를 통해 바이오텍 투자자들로부터 880만 달러의 자금을 확보했습니다. 주요 소식으로는 매튜 록펠러가 HOPE Therapeutics 자문위원회에 합류한 것과 플로리다 팜비치에 플래그십 기관을 설립할 계획이 포함됩니다. 이 결합 치료 접근법은 개별 치료의 통상적인 60%보다 훨씬 높은 90% 이상의 반응률을 목표로 하고 있습니다.
NRx Pharmaceuticals (NASDAQ:NRXP) s'est exprimée au symposium Global Passion Project et a annoncé le lancement prévu pour l'automne 2025 des cliniques HOPE Therapeutics. La société a présenté un programme résidentiel novateur combinant des traitements de neuroplasticité tels que la kétamine, la stimulation magnétique transcrânienne et l'oxygénothérapie hyperbare pour traiter la dépression suicidaire, le SSPT et les troubles cognitifs.
Récemment, la société a obtenu 8,8 millions de dollars de financement auprès d'investisseurs biotech via une émission d'actions ordinaires. Parmi les développements notables figurent l'arrivée de Matthew Rockefeller au conseil consultatif de HOPE Therapeutics et les projets d'établissement d'un site phare à Palm Beach, FL. L'approche thérapeutique combinée vise à atteindre plus de 90 % de taux de réponse, nettement supérieur aux 60 % observés avec des thérapies individuelles.
NRx Pharmaceuticals (NASDAQ:NRXP) präsentierte beim Global Passion Project Symposium Pläne für den Start der HOPE Therapeutics Kliniken im Herbst 2025. Das Unternehmen stellte ein bahnbrechendes stationäres Programm vor, das neuroplastische Behandlungen wie Ketamin, transkranielle Magnetstimulation und hyperbare Sauerstofftherapie zur Behandlung von suizidaler Depression, PTBS und kognitiven Störungen kombiniert.
Das Unternehmen sicherte sich kürzlich 8,8 Millionen US-Dollar an Finanzierung von Biotech-Investoren durch eine Ausgabe von Stammaktien. Zu den bemerkenswerten Entwicklungen zählen Matthew Rockefellers Eintritt in den Beratenden Beirat von HOPE Therapeutics sowie Pläne für einen Flagship-Standort in Palm Beach, FL. Der kombinierte Behandlungsansatz zielt darauf ab, über 90% Ansprechrate zu erreichen, deutlich höher als die üblichen 60% bei Einzeltherapien.
- Secured $8.8 million funding with favorable terms (no warrants or variable rate features)
- Strategic advisory board addition with Matthew Rockefeller joining
- Innovative combined treatment approach targeting 90% response rates
- Multiple revenue streams through diverse treatment modalities
- None.
- NRx CEO presented plans for HOPE Therapeutics rollout in September 2025 and establishment of flagship location in Palm Beach, FL during symposium presentation with leadership from Rockefeller Capital and Matthew Rockefeller.
- Company has recently raised
$8.8 million capital from experienced biotech investors with no warrants, repricing, or other variable rate features. - HOPE clinics will combine treatment with neuroplastic drugs including ketamine, transcranial magnetic stimulation, and hyperbaric oxygen to treat suicidal depression, PTSD, traumatic brain injury and other forms of cognitive dysfunction.
- Matthew Rockefeller is announced as joining the HOPE Therapeutics Advisory Board.
SOUTHAMPTON, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, presented two keynote talks to a gathering of leading family offices and family members sponsored by the Global Passion Project and Rockefeller Capital on August 28-30, 2025 in Southampton, NY. The Company’s CEO, Prof. Jonathan Javitt, MD, MPH spoke alongside Matthew Rockefeller, Bradley Hilton and Cheryl Young of Rockefeller Capital, and representatives of leading family offices to detail plans for the Fall 2025 launch of HOPE Therapeutics clinics and a prospective unique one-week residential program targeting suicidal depression, PTSD, traumatic brain injury, and cognitive dysfunction. The HOPE residential program will be the nation’s first to combine neuroplastic drugs, including ketamine, transcranial magnetic stimulation and hyperbaric oxygen therapy in a campus-like setting that adds nutritional therapy from one of the nation’s leading chefs, neuroplastic-targeted outdoor activities, and supportive therapy. At the symposium, Matthew Rockefeller was announced as joining the advisory board of HOPE Therapeutics.
The presenters and attendees were comprised of members of some of America’s leading legacy families. Andrea Cartier Bartzen, founder of The Global Passion Projects, took the stage to emphasize the foundation’s mission of tackling global challenges, including the current crisis of suicidal depression and PTSD through collaboration and innovation. “By uniting the brightest minds in technology and science with investor and philanthropist visionaries committed to change, we are funding advancements that lead to longer, healthier, and more fulfilling lives,” said Bartzen.
“We welcome Mr. Rockefeller to our advisory board,” said Dr. Javitt. Seventeen years ago, I sat with the daughter of a dear friend the night before his funeral. He was one of the thousands of Americans who die from suicide every 11 minutes. I shared my belief that his death was caused by a biologic “short circuit” in his brain and was no more voluntary than death from a heart attack. Over the subsequent seventeen years scientific advances have continued to point to loss of neuroplasticity – the ability of brain cells to form, prune, and regrow new connections – as an underlying cause of severe depression, PTSD, traumatic brain injury, Parkinson’s disease and other forms of cognitive dysfunction. While NRx continues to advance neuroplastic drug development, including ketamine and cycloserine, our HOPE Therapeutics subsidiary focuses on combining neuroplastic drugs with already-approved neuroplastic treatments including transcranial magnetic stimulation, hyperbaric oxygen therapy, and digital therapeutics. Individually, these treatments have demonstrated
The Company recently raised more than
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new
information, future events or otherwise.
For further information:
| Matthew Duffy | Brian Korb |
| Chief Business Officer, NRx Pharmaceuticals | Managing Partner |
| mduffy@nrxpharma.com | (917) 653-5122 |
| brian.korb@astrpartners.co |
FAQ
When will NRx Pharmaceuticals launch its HOPE Therapeutics clinics?
What treatments will HOPE Therapeutics clinics offer?
How much funding did NRXP recently raise?
What conditions will HOPE Therapeutics treat?
Who joined the HOPE Therapeutics Advisory Board?
